ZA200301082B - Quinazoline derivatives as alpha-1 adrenergic antagonists. - Google Patents

Info

Publication number

ZA200301082B

ZA200301082B ZA200301082A ZA200301082A ZA200301082B ZA 200301082 B ZA200301082 B ZA 200301082B ZA 200301082 A ZA200301082 A ZA 200301082A ZA 200301082 A ZA200301082 A ZA 200301082A ZA 200301082 B ZA200301082 B ZA 200301082B

Authority

ZA

South Africa

Prior art keywords

methyl

amino

phenyl

compound

dimethoxy

Prior art date

2000-08-31

Links

• Espacenet
• Global Dossier
• Discuss

• 239000000674 adrenergic antagonist Substances 0.000 title claims description 16
• 125000002294 quinazolinyl group Chemical class N1=C(N=CC2=CC=CC=C12)* 0.000 title 1
• 150000001875 compounds Chemical class 0.000 claims description 178
• -1 4-amino-6,7-dimethoxy-quinazolin-2-yl Chemical group 0.000 claims description 118
• 239000000203 mixture Substances 0.000 claims description 53
• 125000003545 alkoxy group Chemical group 0.000 claims description 47
• 125000004093 cyano group Chemical group *C#N 0.000 claims description 45
• 229910052736 halogen Inorganic materials 0.000 claims description 44
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 39
• 150000002367 halogens Chemical class 0.000 claims description 38
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 38
• 125000003118 aryl group Chemical group 0.000 claims description 29
• 201000010099 disease Diseases 0.000 claims description 29
• 150000003839 salts Chemical class 0.000 claims description 26
• 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 23
• 125000001072 heteroaryl group Chemical group 0.000 claims description 22
• 125000000623 heterocyclic group Chemical group 0.000 claims description 21
• 239000001257 hydrogen Substances 0.000 claims description 21
• 229910052739 hydrogen Inorganic materials 0.000 claims description 21
• 208000002193 Pain Diseases 0.000 claims description 20
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 19
• 125000003282 alkyl amino group Chemical group 0.000 claims description 18
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 18
• 238000011282 treatment Methods 0.000 claims description 18
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 17
• 239000000651 prodrug Substances 0.000 claims description 17
• 229940002612 prodrug Drugs 0.000 claims description 17
• 239000012453 solvate Substances 0.000 claims description 17
• 125000004423 acyloxy group Chemical group 0.000 claims description 15
• 125000004466 alkoxycarbonylamino group Chemical group 0.000 claims description 15
• 125000003710 aryl alkyl group Chemical group 0.000 claims description 15
• 125000000753 cycloalkyl group Chemical group 0.000 claims description 15
• 125000000217 alkyl group Chemical group 0.000 claims description 14
• 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 14
• 230000036407 pain Effects 0.000 claims description 14
• 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 13
• SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 claims description 12
• 239000008194 pharmaceutical composition Substances 0.000 claims description 12
• 125000001424 substituent group Chemical group 0.000 claims description 12
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 11
• 125000005842 heteroatom Chemical group 0.000 claims description 10
• 208000035475 disorder Diseases 0.000 claims description 9
• 102000000103 Alpha 1B adrenoceptor Human genes 0.000 claims description 8
• 108050008446 Alpha 1B adrenoceptor Proteins 0.000 claims description 8
• 150000002431 hydrogen Chemical class 0.000 claims description 8
• 239000003814 drug Substances 0.000 claims description 7
• 229910052757 nitrogen Inorganic materials 0.000 claims description 7
• 239000000969 carrier Substances 0.000 claims description 6
• 210000001635 urinary tract Anatomy 0.000 claims description 6
• 210000003169 central nervous system Anatomy 0.000 claims description 5
• 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 5
• 125000001153 fluoro group Chemical group F* 0.000 claims description 5
• 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 5
• 230000002265 prevention Effects 0.000 claims description 5
• GHGQPLMWEBWRTF-GOSISDBHSA-N (3r)-1-[4-[[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]methyl]-4-phenylpiperidin-1-yl]-3-hydroxybutan-1-one Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(C)CC1(C=2C=CC=CC=2)CCN(C(=O)C[C@@H](C)O)CC1 GHGQPLMWEBWRTF-GOSISDBHSA-N 0.000 claims description 4
• ONHMOOVKCXOPTA-UHFFFAOYSA-N 1-[4-[[(4-amino-6,7-dimethoxyquinazolin-2-yl)methylamino]methyl]-4-phenylpiperidin-1-yl]-4,4,4-trifluorobutan-1-one Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1CNCC1(C=2C=CC=CC=2)CCN(C(=O)CCC(F)(F)F)CC1 ONHMOOVKCXOPTA-UHFFFAOYSA-N 0.000 claims description 4
• ZIDXCCICXISHCE-UHFFFAOYSA-N 1-[4-[[(4-amino-6,7-dimethoxyquinazolin-2-yl)methylamino]methyl]-4-phenylpiperidin-1-yl]butan-1-one Chemical compound C1CN(C(=O)CCC)CCC1(C=1C=CC=CC=1)CNCC1=NC(N)=C(C=C(OC)C(OC)=C2)C2=N1 ZIDXCCICXISHCE-UHFFFAOYSA-N 0.000 claims description 4
• DQLPHKVITLOLRA-UHFFFAOYSA-N 4-[[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]methyl]-4-phenyl-n-pyridin-3-ylpiperidine-1-carboxamide Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(C)CC(CC1)(C=2C=CC=CC=2)CCN1C(=O)NC1=CC=CN=C1 DQLPHKVITLOLRA-UHFFFAOYSA-N 0.000 claims description 4
• KGWLKUXZQYJSDJ-UHFFFAOYSA-N [4-[[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]methyl]-4-phenylpiperidin-1-yl]-cyclopropylmethanone Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(C)CC(CC1)(C=2C=CC=CC=2)CCN1C(=O)C1CC1 KGWLKUXZQYJSDJ-UHFFFAOYSA-N 0.000 claims description 4
• VMDOPZDZJUGEMS-UHFFFAOYSA-N [4-[[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]methyl]-4-phenylpiperidin-1-yl]-phenylmethanone Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(C)CC(CC1)(C=2C=CC=CC=2)CCN1C(=O)C1=CC=CC=C1 VMDOPZDZJUGEMS-UHFFFAOYSA-N 0.000 claims description 4
• YPRSAAAUAFMTJD-UHFFFAOYSA-N [4-[[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]methyl]-4-phenylpiperidin-1-yl]-pyrrolidin-2-ylmethanone Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(C)CC(CC1)(C=2C=CC=CC=2)CCN1C(=O)C1CCCN1 YPRSAAAUAFMTJD-UHFFFAOYSA-N 0.000 claims description 4
• 239000000951 adrenergic alpha-1 receptor antagonist Substances 0.000 claims description 4
• 229910052717 sulfur Inorganic materials 0.000 claims description 4
• CWFYCDNOWBORKV-UHFFFAOYSA-N 4-[[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]methyl]-n'-methyl-4-phenylpiperidine-1-carboximidamide Chemical compound C1CN(C(=N)NC)CCC1(C=1C=CC=CC=1)CN(C)C1=NC(N)=C(C=C(OC)C(OC)=C2)C2=N1 CWFYCDNOWBORKV-UHFFFAOYSA-N 0.000 claims description 3
• GHGQPLMWEBWRTF-SFHVURJKSA-N (3s)-1-[4-[[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]methyl]-4-phenylpiperidin-1-yl]-3-hydroxybutan-1-one Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(C)CC1(C=2C=CC=CC=2)CCN(C(=O)C[C@H](C)O)CC1 GHGQPLMWEBWRTF-SFHVURJKSA-N 0.000 claims description 2
• XLXDAWFMQFQZGK-UHFFFAOYSA-N 4-[[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]methyl]-n,n-dimethyl-4-phenylpiperidine-1-sulfonamide Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(C)CC1(C=2C=CC=CC=2)CCN(S(=O)(=O)N(C)C)CC1 XLXDAWFMQFQZGK-UHFFFAOYSA-N 0.000 claims description 2
• 201000001880 Sexual dysfunction Diseases 0.000 claims description 2
• 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
• 231100000252 nontoxic Toxicity 0.000 claims description 2
• 230000003000 nontoxic effect Effects 0.000 claims description 2
• 231100000872 sexual dysfunction Toxicity 0.000 claims description 2
• 238000004519 manufacturing process Methods 0.000 claims 3
• CFTNGCJPIFHVSI-UHFFFAOYSA-N 2-n-[(1-cyclopropylsulfonyl-4-phenylpiperidin-4-yl)methyl]-6,7-dimethoxy-2-n-methylquinazoline-2,4-diamine Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(C)CC(CC1)(C=2C=CC=CC=2)CCN1S(=O)(=O)C1CC1 CFTNGCJPIFHVSI-UHFFFAOYSA-N 0.000 claims 1
• 230000006806 disease prevention Effects 0.000 claims 1
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 36
• 238000000034 method Methods 0.000 description 36
• 108020004102 alpha-1 Adrenergic Receptor Proteins 0.000 description 31
• 239000000243 solution Substances 0.000 description 25
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 21
• 241000700159 Rattus Species 0.000 description 20
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
• 102000030619 alpha-1 Adrenergic Receptor Human genes 0.000 description 17
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
• 238000009472 formulation Methods 0.000 description 16
• 239000000843 powder Substances 0.000 description 15
• 238000012360 testing method Methods 0.000 description 15
• 108060003345 Adrenergic Receptor Proteins 0.000 description 14
• 102000017910 Adrenergic receptor Human genes 0.000 description 14
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
• 238000012986 modification Methods 0.000 description 14
• 230000004048 modification Effects 0.000 description 14
• 239000002904 solvent Substances 0.000 description 14
• 206010020853 Hypertonic bladder Diseases 0.000 description 13
• 150000003254 radicals Chemical class 0.000 description 13
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
• 238000006243 chemical reaction Methods 0.000 description 12
• 230000000694 effects Effects 0.000 description 12
• 150000003246 quinazolines Chemical class 0.000 description 12
• 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 11
• 208000004403 Prostatic Hyperplasia Diseases 0.000 description 11
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 11
• 239000005557 antagonist Substances 0.000 description 11
• 239000008280 blood Substances 0.000 description 11
• 210000004369 blood Anatomy 0.000 description 11
• 230000036772 blood pressure Effects 0.000 description 11
• 238000002360 preparation method Methods 0.000 description 11
• 239000007787 solid Substances 0.000 description 11
• 208000024891 symptom Diseases 0.000 description 11
• 239000003826 tablet Substances 0.000 description 11
• 239000004480 active ingredient Substances 0.000 description 10
• 239000002775 capsule Substances 0.000 description 10
• 102100024402 Alpha-1B adrenergic receptor Human genes 0.000 description 9
• 206010020751 Hypersensitivity Diseases 0.000 description 9
• 208000026935 allergic disease Diseases 0.000 description 9
• 239000013078 crystal Substances 0.000 description 9
• 230000009610 hypersensitivity Effects 0.000 description 9
• 239000004615 ingredient Substances 0.000 description 9
• 230000000144 pharmacologic effect Effects 0.000 description 9
• 239000000741 silica gel Substances 0.000 description 9
• 229910002027 silica gel Inorganic materials 0.000 description 9
• 229960001866 silicon dioxide Drugs 0.000 description 9
• 238000003756 stirring Methods 0.000 description 9
• 210000003932 urinary bladder Anatomy 0.000 description 9
• 239000002585 base Substances 0.000 description 8
• 239000002552 dosage form Substances 0.000 description 8
• BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
• 241000282414 Homo sapiens Species 0.000 description 7
• 208000004454 Hyperalgesia Diseases 0.000 description 7
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 7
• 125000004429 atom Chemical group 0.000 description 7
• 125000005843 halogen group Chemical group 0.000 description 7
• 239000000047 product Substances 0.000 description 7
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
• 206010031127 Orthostatic hypotension Diseases 0.000 description 6
• 208000009722 Overactive Urinary Bladder Diseases 0.000 description 6
• KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
• CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
• DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
• 238000003556 assay Methods 0.000 description 6
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 6
• 230000027455 binding Effects 0.000 description 6
• 210000004027 cell Anatomy 0.000 description 6
• 208000014674 injury Diseases 0.000 description 6
• 239000007788 liquid Substances 0.000 description 6
• 208000004296 neuralgia Diseases 0.000 description 6
• 208000020629 overactive bladder Diseases 0.000 description 6
• IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 6
• 201000007094 prostatitis Diseases 0.000 description 6
• 239000000725 suspension Substances 0.000 description 6
• SOYZWGONXBBNMQ-UHFFFAOYSA-N 5-methylquinazoline-2,4-diamine Chemical compound NC1=NC(N)=C2C(C)=CC=CC2=N1 SOYZWGONXBBNMQ-UHFFFAOYSA-N 0.000 description 5
• 208000019901 Anxiety disease Diseases 0.000 description 5
• 241001465754 Metazoa Species 0.000 description 5
• 239000002253 acid Substances 0.000 description 5
• 125000004453 alkoxycarbonyl group Chemical group 0.000 description 5
• 125000004457 alkyl amino carbonyl group Chemical group 0.000 description 5
• 102000015009 alpha1-adrenergic receptor activity proteins Human genes 0.000 description 5
• 208000015114 central nervous system disease Diseases 0.000 description 5
• 201000003146 cystitis Diseases 0.000 description 5
• 239000000839 emulsion Substances 0.000 description 5
• 125000001188 haloalkyl group Chemical group 0.000 description 5
• 210000002216 heart Anatomy 0.000 description 5
• 125000002768 hydroxyalkyl group Chemical group 0.000 description 5
• 238000001727 in vivo Methods 0.000 description 5
• 239000000463 material Substances 0.000 description 5
• 230000027939 micturition Effects 0.000 description 5
• 208000028173 post-traumatic stress disease Diseases 0.000 description 5
• 229960001289 prazosin Drugs 0.000 description 5
• 125000006239 protecting group Chemical group 0.000 description 5
• 239000011541 reaction mixture Substances 0.000 description 5
• 201000000980 schizophrenia Diseases 0.000 description 5
• 239000007921 spray Substances 0.000 description 5
• 239000000126 substance Substances 0.000 description 5
• 210000001519 tissue Anatomy 0.000 description 5
• 208000000143 urethritis Diseases 0.000 description 5
• 239000003981 vehicle Substances 0.000 description 5
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
• HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
• 206010065390 Inflammatory pain Diseases 0.000 description 4
• 241000124008 Mammalia Species 0.000 description 4
• 206010036968 Prostatic pain Diseases 0.000 description 4
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
• 208000000921 Urge Urinary Incontinence Diseases 0.000 description 4
• 208000026723 Urinary tract disease Diseases 0.000 description 4
• 230000009471 action Effects 0.000 description 4
• 208000005298 acute pain Diseases 0.000 description 4
• 125000004471 alkyl aminosulfonyl group Chemical group 0.000 description 4
• 125000003806 alkyl carbonyl amino group Chemical group 0.000 description 4
• 125000004390 alkyl sulfonyl group Chemical group 0.000 description 4
• 125000004656 alkyl sulfonylamino group Chemical group 0.000 description 4
• 125000004414 alkyl thio group Chemical group 0.000 description 4
• 125000005100 aryl amino carbonyl group Chemical group 0.000 description 4
• 125000005141 aryl amino sulfonyl group Chemical group 0.000 description 4
• 125000004657 aryl sulfonyl amino group Chemical group 0.000 description 4
• 125000004391 aryl sulfonyl group Chemical group 0.000 description 4
• 239000003153 chemical reaction reagent Substances 0.000 description 4
• 239000003795 chemical substances by application Substances 0.000 description 4
• 230000007812 deficiency Effects 0.000 description 4
• 229940079593 drug Drugs 0.000 description 4
• 239000007937 lozenge Substances 0.000 description 4
• 239000012528 membrane Substances 0.000 description 4
• 229940097496 nasal spray Drugs 0.000 description 4
• 239000007922 nasal spray Substances 0.000 description 4
• 208000021722 neuropathic pain Diseases 0.000 description 4
• 229910000027 potassium carbonate Inorganic materials 0.000 description 4
• 230000008569 process Effects 0.000 description 4
• 230000009467 reduction Effects 0.000 description 4
• 208000019116 sleep disease Diseases 0.000 description 4
• 239000003381 stabilizer Substances 0.000 description 4
• 239000000829 suppository Substances 0.000 description 4
• 239000000375 suspending agent Substances 0.000 description 4
• 238000013268 sustained release Methods 0.000 description 4
• 230000002889 sympathetic effect Effects 0.000 description 4
• 230000001225 therapeutic effect Effects 0.000 description 4
• 239000002562 thickening agent Substances 0.000 description 4
• 230000008733 trauma Effects 0.000 description 4
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
• 206010046494 urge incontinence Diseases 0.000 description 4
• KGULWBQOMUWTTR-UHFFFAOYSA-N 1-[4-[[(4-amino-6,7-dimethoxyquinazolin-2-yl)methylamino]methyl]-4-(4-fluorophenyl)piperidin-1-yl]butan-1-one Chemical compound C1CN(C(=O)CCC)CCC1(C=1C=CC(F)=CC=1)CNCC1=NC(N)=C(C=C(OC)C(OC)=C2)C2=N1 KGULWBQOMUWTTR-UHFFFAOYSA-N 0.000 description 3
• ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
• QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 3
• 241000220479 Acacia Species 0.000 description 3
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
• 102000009368 Alpha 1D adrenoceptor Human genes 0.000 description 3
• 108050000241 Alpha 1D adrenoceptor Proteins 0.000 description 3
• UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
• 208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 3
• 206010010904 Convulsion Diseases 0.000 description 3
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
• 108010010803 Gelatin Proteins 0.000 description 3
• 206010021639 Incontinence Diseases 0.000 description 3
• 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
• 206010027566 Micturition urgency Diseases 0.000 description 3
• LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
• 208000000450 Pelvic Pain Diseases 0.000 description 3
• 206010036018 Pollakiuria Diseases 0.000 description 3
• KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
• 208000028017 Psychotic disease Diseases 0.000 description 3
• 239000007983 Tris buffer Substances 0.000 description 3
• 208000027418 Wounds and injury Diseases 0.000 description 3
• CLDHYZHTRGERAT-UHFFFAOYSA-N [4-[[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]methyl]-4-phenylpiperidin-1-yl]-(oxolan-2-yl)methanone Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(C)CC(CC1)(C=2C=CC=CC=2)CCN1C(=O)C1CCCO1 CLDHYZHTRGERAT-UHFFFAOYSA-N 0.000 description 3
• 238000010521 absorption reaction Methods 0.000 description 3
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
• 230000036506 anxiety Effects 0.000 description 3
• 239000007900 aqueous suspension Substances 0.000 description 3
• KVNRLNFWIYMESJ-UHFFFAOYSA-N butyronitrile Chemical compound CCCC#N KVNRLNFWIYMESJ-UHFFFAOYSA-N 0.000 description 3
• 239000001768 carboxy methyl cellulose Substances 0.000 description 3
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
• 239000003086 colorant Substances 0.000 description 3
• 230000008602 contraction Effects 0.000 description 3
• 239000006071 cream Substances 0.000 description 3
• 150000004985 diamines Chemical class 0.000 description 3
• 239000003085 diluting agent Substances 0.000 description 3
• QKIUAMUSENSFQQ-UHFFFAOYSA-N dimethylazanide Chemical compound C[N-]C QKIUAMUSENSFQQ-UHFFFAOYSA-N 0.000 description 3
• 239000002270 dispersing agent Substances 0.000 description 3
• 239000003937 drug carrier Substances 0.000 description 3
• 238000003818 flash chromatography Methods 0.000 description 3
• 239000000796 flavoring agent Substances 0.000 description 3
• 239000012530 fluid Substances 0.000 description 3
• 210000002683 foot Anatomy 0.000 description 3
• 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 3
• 239000008273 gelatin Substances 0.000 description 3
• 229920000159 gelatin Polymers 0.000 description 3
• 235000019322 gelatine Nutrition 0.000 description 3
• 235000011852 gelatine desserts Nutrition 0.000 description 3
• 239000011521 glass Substances 0.000 description 3
• 238000005462 in vivo assay Methods 0.000 description 3
• 239000012442 inert solvent Substances 0.000 description 3
• 238000002347 injection Methods 0.000 description 3
• 239000007924 injection Substances 0.000 description 3
• 238000001990 intravenous administration Methods 0.000 description 3
• 210000004185 liver Anatomy 0.000 description 3
• 238000002844 melting Methods 0.000 description 3
• 230000008018 melting Effects 0.000 description 3
• 206010029446 nocturia Diseases 0.000 description 3
• 229920006316 polyvinylpyrrolidine Polymers 0.000 description 3
• 210000002307 prostate Anatomy 0.000 description 3
• 108090000623 proteins and genes Proteins 0.000 description 3
• XELRMPRLCPFTBH-UHFFFAOYSA-N quinazoline-2,4-diamine Chemical compound C1=CC=CC2=NC(N)=NC(N)=C21 XELRMPRLCPFTBH-UHFFFAOYSA-N 0.000 description 3
• 102000005962 receptors Human genes 0.000 description 3
• 108020003175 receptors Proteins 0.000 description 3
• 230000002829 reductive effect Effects 0.000 description 3
• 238000010992 reflux Methods 0.000 description 3
• 208000012672 seasonal affective disease Diseases 0.000 description 3
• 229910000029 sodium carbonate Inorganic materials 0.000 description 3
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
• 210000000278 spinal cord Anatomy 0.000 description 3
• 230000006641 stabilisation Effects 0.000 description 3
• 238000011105 stabilization Methods 0.000 description 3
• 239000013589 supplement Substances 0.000 description 3
• 239000012730 sustained-release form Substances 0.000 description 3
• 208000022934 urinary frequency Diseases 0.000 description 3
• 230000036318 urination frequency Effects 0.000 description 3
• JDKYQMGJJXSZCE-UHFFFAOYSA-N 1-(1-benzyl-4-phenylpiperidin-4-yl)-n-methylmethanamine Chemical compound C1CC(CNC)(C=2C=CC=CC=2)CCN1CC1=CC=CC=C1 JDKYQMGJJXSZCE-UHFFFAOYSA-N 0.000 description 2
• UPAFYYARYFDQBO-UHFFFAOYSA-N 1-[4-[[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]methyl]-4-phenylpiperidin-1-yl]-2-phenylethanone Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(C)CC(CC1)(C=2C=CC=CC=2)CCN1C(=O)CC1=CC=CC=C1 UPAFYYARYFDQBO-UHFFFAOYSA-N 0.000 description 2
• DCEPEDFEMWRDKR-UHFFFAOYSA-N 1-[4-[[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]methyl]-4-phenylpiperidin-1-yl]-4-hydroxybutan-1-one Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(C)CC1(C=2C=CC=CC=2)CCN(C(=O)CCCO)CC1 DCEPEDFEMWRDKR-UHFFFAOYSA-N 0.000 description 2
• AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 2
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
• CWKXDPPQCVWXAG-UHFFFAOYSA-N 2,3-dihydro-1,4-benzodioxine-6-carbaldehyde Chemical compound O1CCOC2=CC(C=O)=CC=C21 CWKXDPPQCVWXAG-UHFFFAOYSA-N 0.000 description 2
• HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
• OKDGRDCXVWSXDC-UHFFFAOYSA-N 2-chloropyridine Chemical compound ClC1=CC=CC=N1 OKDGRDCXVWSXDC-UHFFFAOYSA-N 0.000 description 2
• SMNDYUVBFMFKNZ-UHFFFAOYSA-N 2-furoic acid Chemical compound OC(=O)C1=CC=CO1 SMNDYUVBFMFKNZ-UHFFFAOYSA-N 0.000 description 2
• SHVVSKCXWMEDRW-UHFFFAOYSA-N 3-isocyanatopyridine Chemical compound O=C=NC1=CC=CN=C1 SHVVSKCXWMEDRW-UHFFFAOYSA-N 0.000 description 2
• BJFVHAABELIYAQ-UHFFFAOYSA-N 4-[[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]methyl]-4-phenylpiperidine-1-carboxylic acid Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(C)CC1(C=2C=CC=CC=2)CCN(C(O)=O)CC1 BJFVHAABELIYAQ-UHFFFAOYSA-N 0.000 description 2
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
• 102000019269 Alpha 1A adrenoceptor Human genes 0.000 description 2
• 108050006749 Alpha 1A adrenoceptor Proteins 0.000 description 2
• 206010002091 Anaesthesia Diseases 0.000 description 2
• 241000416162 Astragalus gummifer Species 0.000 description 2
• 206010003805 Autism Diseases 0.000 description 2
• 208000020706 Autistic disease Diseases 0.000 description 2
• 208000020925 Bipolar disease Diseases 0.000 description 2
• 241000283690 Bos taurus Species 0.000 description 2
• 208000032841 Bulimia Diseases 0.000 description 2
• 206010006550 Bulimia nervosa Diseases 0.000 description 2
• 239000004255 Butylated hydroxyanisole Substances 0.000 description 2
• 241000282472 Canis lupus familiaris Species 0.000 description 2
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
• 229910021591 Copper(I) chloride Inorganic materials 0.000 description 2
• RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
• AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
• 208000005615 Interstitial Cystitis Diseases 0.000 description 2
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
• CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
• 206010026749 Mania Diseases 0.000 description 2
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
• JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
• 206010029412 Nightmare Diseases 0.000 description 2
• 206010061876 Obstruction Diseases 0.000 description 2
• 206010033864 Paranoia Diseases 0.000 description 2
• 208000027099 Paranoid disease Diseases 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
• 239000004698 Polyethylene Substances 0.000 description 2
• 239000002202 Polyethylene glycol Substances 0.000 description 2
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
• SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
• 229920002472 Starch Polymers 0.000 description 2
• 229930006000 Sucrose Natural products 0.000 description 2
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
• DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
• 229920001615 Tragacanth Polymers 0.000 description 2
• GIYYKWUCDTVWCS-UHFFFAOYSA-N [4-[[(4-amino-6,7-dimethoxyquinazolin-2-yl)amino]methyl]-4-phenylpiperidin-1-yl]-(furan-2-yl)methanone Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1NCC(CC1)(C=2C=CC=CC=2)CCN1C(=O)C1=CC=CO1 GIYYKWUCDTVWCS-UHFFFAOYSA-N 0.000 description 2
• 150000007513 acids Chemical class 0.000 description 2
• 239000000443 aerosol Substances 0.000 description 2
• 230000001668 ameliorated effect Effects 0.000 description 2
• VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 2
• 230000037005 anaesthesia Effects 0.000 description 2
• 230000000202 analgesic effect Effects 0.000 description 2
• 208000022531 anorexia Diseases 0.000 description 2
• 239000000164 antipsychotic agent Substances 0.000 description 2
• 239000007864 aqueous solution Substances 0.000 description 2
• 150000005840 aryl radicals Chemical class 0.000 description 2
• 230000006399 behavior Effects 0.000 description 2
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
• 230000004531 blood pressure lowering effect Effects 0.000 description 2
• 210000004556 brain Anatomy 0.000 description 2
• 239000000872 buffer Substances 0.000 description 2
• 235000019282 butylated hydroxyanisole Nutrition 0.000 description 2
• 229940043253 butylated hydroxyanisole Drugs 0.000 description 2
• CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 2
• 125000004744 butyloxycarbonyl group Chemical group 0.000 description 2
• 125000004432 carbon atom Chemical group C* 0.000 description 2
• 239000003054 catalyst Substances 0.000 description 2
• 210000003710 cerebral cortex Anatomy 0.000 description 2
• 125000001309 chloro group Chemical group Cl* 0.000 description 2
• ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
• 229940110456 cocoa butter Drugs 0.000 description 2
• 235000019868 cocoa butter Nutrition 0.000 description 2
• 229940126214 compound 3 Drugs 0.000 description 2
• OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 2
• 239000012043 crude product Substances 0.000 description 2
• 238000002425 crystallisation Methods 0.000 description 2
• 230000008025 crystallization Effects 0.000 description 2
• ZOOSILUVXHVRJE-UHFFFAOYSA-N cyclopropanecarbonyl chloride Chemical compound ClC(=O)C1CC1 ZOOSILUVXHVRJE-UHFFFAOYSA-N 0.000 description 2
• 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 2
• 230000006378 damage Effects 0.000 description 2
• 238000006264 debenzylation reaction Methods 0.000 description 2
• 206010061428 decreased appetite Diseases 0.000 description 2
• 230000006735 deficit Effects 0.000 description 2
• PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 2
• XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
• ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
• 238000012377 drug delivery Methods 0.000 description 2
• 239000003995 emulsifying agent Substances 0.000 description 2
• RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 2
• 238000002474 experimental method Methods 0.000 description 2
• 210000001105 femoral artery Anatomy 0.000 description 2
• 210000003191 femoral vein Anatomy 0.000 description 2
• 239000000706 filtrate Substances 0.000 description 2
• 235000019634 flavors Nutrition 0.000 description 2
• 230000006870 function Effects 0.000 description 2
• 125000002541 furyl group Chemical group 0.000 description 2
• 239000000499 gel Substances 0.000 description 2
• BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 2
• 230000036541 health Effects 0.000 description 2
• 238000005984 hydrogenation reaction Methods 0.000 description 2
• 208000015181 infectious disease Diseases 0.000 description 2
• 230000002458 infectious effect Effects 0.000 description 2
• 238000001802 infusion Methods 0.000 description 2
• 150000007529 inorganic bases Chemical class 0.000 description 2
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
• 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 2
• JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
• 239000008101 lactose Substances 0.000 description 2
• 239000000787 lecithin Substances 0.000 description 2
• 235000010445 lecithin Nutrition 0.000 description 2
• 229940067606 lecithin Drugs 0.000 description 2
• 239000006210 lotion Substances 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 230000000873 masking effect Effects 0.000 description 2
• 230000004060 metabolic process Effects 0.000 description 2
• 229920000609 methyl cellulose Polymers 0.000 description 2
• 239000001923 methylcellulose Substances 0.000 description 2
• 235000010981 methylcellulose Nutrition 0.000 description 2
• LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
• TXXHDPDFNKHHGW-UHFFFAOYSA-N muconic acid Chemical compound OC(=O)C=CC=CC(O)=O TXXHDPDFNKHHGW-UHFFFAOYSA-N 0.000 description 2
• JFCHSQDLLFJHOA-UHFFFAOYSA-N n,n-dimethylsulfamoyl chloride Chemical compound CN(C)S(Cl)(=O)=O JFCHSQDLLFJHOA-UHFFFAOYSA-N 0.000 description 2
• 210000003928 nasal cavity Anatomy 0.000 description 2
• 210000002569 neuron Anatomy 0.000 description 2
• 239000002674 ointment Substances 0.000 description 2
• 230000003287 optical effect Effects 0.000 description 2
• 210000000056 organ Anatomy 0.000 description 2
• 150000007530 organic bases Chemical class 0.000 description 2
• 239000012074 organic phase Substances 0.000 description 2
• 229910052760 oxygen Inorganic materials 0.000 description 2
• 239000002245 particle Substances 0.000 description 2
• 239000002953 phosphate buffered saline Substances 0.000 description 2
• 239000006187 pill Substances 0.000 description 2
• 229920000573 polyethylene Polymers 0.000 description 2
• 229920001223 polyethylene glycol Polymers 0.000 description 2
• 238000011176 pooling Methods 0.000 description 2
• 230000003389 potentiating effect Effects 0.000 description 2
• 239000003755 preservative agent Substances 0.000 description 2
• DRINJBFRTLBHNF-UHFFFAOYSA-N propane-2-sulfonyl chloride Chemical compound CC(C)S(Cl)(=O)=O DRINJBFRTLBHNF-UHFFFAOYSA-N 0.000 description 2
• 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
• 239000002287 radioligand Substances 0.000 description 2
• 230000004044 response Effects 0.000 description 2
• YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
• 210000002460 smooth muscle Anatomy 0.000 description 2
• 241000894007 species Species 0.000 description 2
• 230000000087 stabilizing effect Effects 0.000 description 2
• 239000008107 starch Substances 0.000 description 2
• 235000019698 starch Nutrition 0.000 description 2
• 239000007858 starting material Substances 0.000 description 2
• 230000000638 stimulation Effects 0.000 description 2
• UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
• 238000007920 subcutaneous administration Methods 0.000 description 2
• 239000005720 sucrose Substances 0.000 description 2
• 238000001356 surgical procedure Methods 0.000 description 2
• 230000002459 sustained effect Effects 0.000 description 2
• 208000011580 syndromic disease Diseases 0.000 description 2
• 238000003786 synthesis reaction Methods 0.000 description 2
• YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
• 238000002560 therapeutic procedure Methods 0.000 description 2
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
• 238000011200 topical administration Methods 0.000 description 2
• 235000010487 tragacanth Nutrition 0.000 description 2
• 239000000196 tragacanth Substances 0.000 description 2
• 229940116362 tragacanth Drugs 0.000 description 2
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
• 210000003708 urethra Anatomy 0.000 description 2
• 230000002485 urinary effect Effects 0.000 description 2
• 208000014001 urinary system disease Diseases 0.000 description 2
• 239000008215 water for injection Substances 0.000 description 2
• SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
• SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
• QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
• YONLFQNRGZXBBF-ZIAGYGMSSA-N (2r,3r)-2,3-dibenzoyloxybutanedioic acid Chemical compound O([C@@H](C(=O)O)[C@@H](OC(=O)C=1C=CC=CC=1)C(O)=O)C(=O)C1=CC=CC=C1 YONLFQNRGZXBBF-ZIAGYGMSSA-N 0.000 description 1
• CCNCITSJXCSXJY-UHFFFAOYSA-N (3,4-dichlorophenyl)thiourea Chemical compound NC(=S)NC1=CC=C(Cl)C(Cl)=C1 CCNCITSJXCSXJY-UHFFFAOYSA-N 0.000 description 1
• SJHPCNCNNSSLPL-CSKARUKUSA-N (4e)-4-(ethoxymethylidene)-2-phenyl-1,3-oxazol-5-one Chemical class O1C(=O)C(=C/OCC)\N=C1C1=CC=CC=C1 SJHPCNCNNSSLPL-CSKARUKUSA-N 0.000 description 1
• UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
• 229930182837 (R)-adrenaline Natural products 0.000 description 1
• MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
• BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
• SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
• ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
• WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
• DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
• NEWVZDKSLFFWQQ-UHFFFAOYSA-N 1-[4-[[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]methyl]-4-phenylpiperidin-1-yl]-2,2-dimethylpropan-1-one Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(C)CC1(C=2C=CC=CC=2)CCN(C(=O)C(C)(C)C)CC1 NEWVZDKSLFFWQQ-UHFFFAOYSA-N 0.000 description 1
• VUTODOMSEMOEFW-UHFFFAOYSA-N 1-[4-[[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]methyl]-4-phenylpiperidin-1-yl]-2-(methylamino)ethanone Chemical compound C1CN(C(=O)CNC)CCC1(C=1C=CC=CC=1)CN(C)C1=NC(N)=C(C=C(OC)C(OC)=C2)C2=N1 VUTODOMSEMOEFW-UHFFFAOYSA-N 0.000 description 1
• MDYZXZKUTKDAGF-UHFFFAOYSA-N 1-[4-[[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]methyl]-4-phenylpiperidin-1-yl]-2-cyclopropylethanone Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(C)CC(CC1)(C=2C=CC=CC=2)CCN1C(=O)CC1CC1 MDYZXZKUTKDAGF-UHFFFAOYSA-N 0.000 description 1
• CIIBEEDZNDOMNP-UHFFFAOYSA-N 1-[4-[[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]methyl]-4-phenylpiperidin-1-yl]-2-hydroxyethanone Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(C)CC1(C=2C=CC=CC=2)CCN(C(=O)CO)CC1 CIIBEEDZNDOMNP-UHFFFAOYSA-N 0.000 description 1
• QMZBEMOBLIEUIE-UHFFFAOYSA-N 1-[4-[[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]methyl]-4-phenylpiperidin-1-yl]-2-methoxyethanone Chemical compound C1CN(C(=O)COC)CCC1(C=1C=CC=CC=1)CN(C)C1=NC(N)=C(C=C(OC)C(OC)=C2)C2=N1 QMZBEMOBLIEUIE-UHFFFAOYSA-N 0.000 description 1
• KGOCGDUBIVOFND-UHFFFAOYSA-N 1-[4-[[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]methyl]-4-phenylpiperidin-1-yl]-2-methylpropan-1-one Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(C)CC1(C=2C=CC=CC=2)CCN(C(=O)C(C)C)CC1 KGOCGDUBIVOFND-UHFFFAOYSA-N 0.000 description 1
• BEKCNEKHWHHPOG-UHFFFAOYSA-N 1-[4-[[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]methyl]-4-phenylpiperidin-1-yl]-2-pyridin-2-ylethanone Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(C)CC(CC1)(C=2C=CC=CC=2)CCN1C(=O)CC1=CC=CC=N1 BEKCNEKHWHHPOG-UHFFFAOYSA-N 0.000 description 1
• RJFFLJATWYKEOS-UHFFFAOYSA-N 1-[4-[[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]methyl]-4-phenylpiperidin-1-yl]-3-hydroxypropan-1-one Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(C)CC1(C=2C=CC=CC=2)CCN(C(=O)CCO)CC1 RJFFLJATWYKEOS-UHFFFAOYSA-N 0.000 description 1
• FTNPHQZZPGIHAX-UHFFFAOYSA-N 1-[4-[[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]methyl]-4-phenylpiperidin-1-yl]-3-methylbutan-1-one Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(C)CC1(C=2C=CC=CC=2)CCN(C(=O)CC(C)C)CC1 FTNPHQZZPGIHAX-UHFFFAOYSA-N 0.000 description 1
• NNXBEOXJCGYDQM-UHFFFAOYSA-N 1-[4-[[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]methyl]-4-thiophen-2-ylpiperidin-1-yl]butan-1-one Chemical compound C1CN(C(=O)CCC)CCC1(C=1SC=CC=1)CN(C)C1=NC(N)=C(C=C(OC)C(OC)=C2)C2=N1 NNXBEOXJCGYDQM-UHFFFAOYSA-N 0.000 description 1
• SYGBEFXFAXECMX-UHFFFAOYSA-N 1-[4-[[(4-amino-6,7-dimethoxyquinazolin-2-yl)methylamino]methyl]-4-(2-methoxyphenyl)piperidin-1-yl]butan-1-one Chemical compound C1CN(C(=O)CCC)CCC1(C=1C(=CC=CC=1)OC)CNCC1=NC(N)=C(C=C(OC)C(OC)=C2)C2=N1 SYGBEFXFAXECMX-UHFFFAOYSA-N 0.000 description 1
• SUSKQAQPXYOGNX-UHFFFAOYSA-N 1-[4-[[(4-amino-6,7-dimethoxyquinazolin-2-yl)methylamino]methyl]-4-(4-methoxyphenyl)piperidin-1-yl]butan-1-one Chemical compound C1CN(C(=O)CCC)CCC1(C=1C=CC(OC)=CC=1)CNCC1=NC(N)=C(C=C(OC)C(OC)=C2)C2=N1 SUSKQAQPXYOGNX-UHFFFAOYSA-N 0.000 description 1
• SFZNQPSCXIRWIC-UHFFFAOYSA-N 1-[4-[[(4-amino-6,7-dimethoxyquinazolin-2-yl)methylamino]methyl]-4-methylpiperidin-1-yl]butan-1-one Chemical compound C1CN(C(=O)CCC)CCC1(C)CNCC1=NC(N)=C(C=C(OC)C(OC)=C2)C2=N1 SFZNQPSCXIRWIC-UHFFFAOYSA-N 0.000 description 1
• LBZZEDLAEDLJCB-UHFFFAOYSA-N 1-[4-[[(4-amino-6,7-dimethoxyquinazolin-2-yl)methylamino]methyl]-4-phenylpiperidin-1-yl]-2-hydroxy-2-methylpropan-1-one Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1CNCC1(C=2C=CC=CC=2)CCN(C(=O)C(C)(C)O)CC1 LBZZEDLAEDLJCB-UHFFFAOYSA-N 0.000 description 1
• HHHOGBSTJNAKGC-UHFFFAOYSA-N 1-[4-[[(4-amino-6,7-dimethoxyquinazolin-2-yl)methylamino]methyl]-4-phenylpiperidin-1-yl]-3-hydroxy-2,2-dimethylpropan-1-one Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1CNCC1(C=2C=CC=CC=2)CCN(C(=O)C(C)(C)CO)CC1 HHHOGBSTJNAKGC-UHFFFAOYSA-N 0.000 description 1
• MYYGOYOKFVEPGL-UHFFFAOYSA-N 1-[4-[[(4-amino-6,7-dimethoxyquinazolin-2-yl)methylamino]methyl]-4-phenylpiperidin-1-yl]-3-hydroxy-3-methylbutan-1-one Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1CNCC1(C=2C=CC=CC=2)CCN(C(=O)CC(C)(C)O)CC1 MYYGOYOKFVEPGL-UHFFFAOYSA-N 0.000 description 1
• WRZGVONRPLHOHK-UHFFFAOYSA-N 1-[4-[[(4-amino-6,7-dimethoxyquinazolin-2-yl)methylamino]methyl]-4-phenylpiperidin-1-yl]-3-hydroxybutan-1-one Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1CNCC1(C=2C=CC=CC=2)CCN(C(=O)CC(C)O)CC1 WRZGVONRPLHOHK-UHFFFAOYSA-N 0.000 description 1
• XJDMRUBBUURLSS-UHFFFAOYSA-N 1-[4-[[(4-amino-6,7-dimethoxyquinazolin-2-yl)methylamino]methyl]-4-phenylpiperidin-1-yl]butane-1,3-dione Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1CNCC1(C=2C=CC=CC=2)CCN(C(=O)CC(C)=O)CC1 XJDMRUBBUURLSS-UHFFFAOYSA-N 0.000 description 1
• ODQMWHOTLRCVMT-UHFFFAOYSA-N 1-[4-[[(4-amino-6,7-dimethoxyquinazolin-2-yl)methylamino]methyl]-4-phenylpiperidin-1-yl]propan-1-one Chemical compound C1CN(C(=O)CC)CCC1(C=1C=CC=CC=1)CNCC1=NC(N)=C(C=C(OC)C(OC)=C2)C2=N1 ODQMWHOTLRCVMT-UHFFFAOYSA-N 0.000 description 1
• WLXGQMVCYPUOLM-UHFFFAOYSA-N 1-hydroxyethanesulfonic acid Chemical compound CC(O)S(O)(=O)=O WLXGQMVCYPUOLM-UHFFFAOYSA-N 0.000 description 1
• 238000005160 1H NMR spectroscopy Methods 0.000 description 1
• 125000000453 2,2,2-trichloroethyl group Chemical group [H]C([H])(*)C(Cl)(Cl)Cl 0.000 description 1
• 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
• OZFHIWMMAHHJQN-UHFFFAOYSA-N 2-[[4-[[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]methyl]-4-phenylpiperidin-1-yl]methyl]benzonitrile Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(C)CC(CC1)(C=2C=CC=CC=2)CCN1CC1=CC=CC=C1C#N OZFHIWMMAHHJQN-UHFFFAOYSA-N 0.000 description 1
• PVUQHDJKYHILFU-UHFFFAOYSA-N 2-amino-1-[4-[[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]methyl]-4-phenylpiperidin-1-yl]-3-phenylpropan-1-one Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(C)CC(CC1)(C=2C=CC=CC=2)CCN1C(=O)C(N)CC1=CC=CC=C1 PVUQHDJKYHILFU-UHFFFAOYSA-N 0.000 description 1
• XGVUQBJSXLSZQD-UHFFFAOYSA-N 2-amino-1-[4-[[(4-amino-6,7-dimethoxyquinazolin-2-yl)methylamino]methyl]-4-phenylpiperidin-1-yl]ethanone Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1CNCC1(C=2C=CC=CC=2)CCN(C(=O)CN)CC1 XGVUQBJSXLSZQD-UHFFFAOYSA-N 0.000 description 1
• VZHOUEQLAZZYKK-UHFFFAOYSA-N 2-chloro-4,5-dihydro-1h-imidazole;sulfuric acid Chemical compound OS(O)(=O)=O.ClC1=NCCN1 VZHOUEQLAZZYKK-UHFFFAOYSA-N 0.000 description 1
• LBMRLXOTDIRNJN-UHFFFAOYSA-N 2-chloro-6,7-dimethylquinazolin-4-amine Chemical compound ClC1=NC(N)=C2C=C(C)C(C)=CC2=N1 LBMRLXOTDIRNJN-UHFFFAOYSA-N 0.000 description 1
• 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
• UPHOPMSGKZNELG-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=C(O)C=CC2=C1 UPHOPMSGKZNELG-UHFFFAOYSA-N 0.000 description 1
• HDMQGFZQRPAZKA-UHFFFAOYSA-N 2-n-[[1-[(2-ethoxyphenyl)methyl]-4-phenylpiperidin-4-yl]methyl]-6,7-dimethoxy-2-n-methylquinazoline-2,4-diamine Chemical compound CCOC1=CC=CC=C1CN1CCC(CN(C)C=2N=C3C=C(OC)C(OC)=CC3=C(N)N=2)(C=2C=CC=CC=2)CC1 HDMQGFZQRPAZKA-UHFFFAOYSA-N 0.000 description 1
• FJNLCHNQVJVCPY-UHFFFAOYSA-N 2-n-methoxy-2-n-methyl-4-n,6-n-dipropyl-1,3,5-triazine-2,4,6-triamine Chemical compound CCCNC1=NC(NCCC)=NC(N(C)OC)=N1 FJNLCHNQVJVCPY-UHFFFAOYSA-N 0.000 description 1
• KDEFMIDHGFDTKU-UHFFFAOYSA-N 3-amino-1-[4-[[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]methyl]-4-phenylpiperidin-1-yl]-3-methylbutan-1-one Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(C)CC1(C=2C=CC=CC=2)CCN(C(=O)CC(C)(C)N)CC1 KDEFMIDHGFDTKU-UHFFFAOYSA-N 0.000 description 1
• FDHRKHTUADXBQF-UHFFFAOYSA-N 3-amino-1-[4-[[(4-amino-6,7-dimethoxyquinazolin-2-yl)methylamino]methyl]-4-phenylpiperidin-1-yl]propan-1-one Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1CNCC1(C=2C=CC=CC=2)CCN(C(=O)CCN)CC1 FDHRKHTUADXBQF-UHFFFAOYSA-N 0.000 description 1
• CUYKNJBYIJFRCU-UHFFFAOYSA-N 3-aminopyridine Chemical compound NC1=CC=CN=C1 CUYKNJBYIJFRCU-UHFFFAOYSA-N 0.000 description 1
• BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
• QZVQQUVWFIZUBQ-UHFFFAOYSA-N 3-fluoroaniline Chemical compound NC1=CC=CC(F)=C1 QZVQQUVWFIZUBQ-UHFFFAOYSA-N 0.000 description 1
• QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 1
• 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• UKMHZXNENWTLOY-UHFFFAOYSA-N 4-[[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]methyl]-4-(4-fluorophenyl)-n-pyridin-3-ylpiperidine-1-carboxamide Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(C)CC(CC1)(C=2C=CC(F)=CC=2)CCN1C(=O)NC1=CC=CN=C1 UKMHZXNENWTLOY-UHFFFAOYSA-N 0.000 description 1
• HJCJTCBDKFALAT-UHFFFAOYSA-N 4-[[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]methyl]-4-morpholin-4-yl-n-phenylpiperidine-1-carboxamide Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(C)CC(CC1)(N2CCOCC2)CCN1C(=O)NC1=CC=CC=C1 HJCJTCBDKFALAT-UHFFFAOYSA-N 0.000 description 1
• VYMBKSYYUASIBC-UHFFFAOYSA-N 4-[[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]methyl]-n'-(2-ethylphenyl)-4-phenylpiperidine-1-carboximidamide Chemical compound CCC1=CC=CC=C1NC(=N)N1CCC(CN(C)C=2N=C3C=C(OC)C(OC)=CC3=C(N)N=2)(C=2C=CC=CC=2)CC1 VYMBKSYYUASIBC-UHFFFAOYSA-N 0.000 description 1
• SUUDLURUHSWCRR-UHFFFAOYSA-N 4-[[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]methyl]-n'-(3-chlorophenyl)-4-phenylpiperidine-1-carboximidamide Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(C)CC(CC1)(C=2C=CC=CC=2)CCN1C(=N)NC1=CC=CC(Cl)=C1 SUUDLURUHSWCRR-UHFFFAOYSA-N 0.000 description 1
• QBVFHBBWOFBHHN-UHFFFAOYSA-N 4-[[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]methyl]-n'-(4-fluorophenyl)-4-phenylpiperidine-1-carboximidamide Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(C)CC(CC1)(C=2C=CC=CC=2)CCN1C(=N)NC1=CC=C(F)C=C1 QBVFHBBWOFBHHN-UHFFFAOYSA-N 0.000 description 1
• FHIWFUNBVHTOAO-UHFFFAOYSA-N 4-[[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]methyl]-n'-ethyl-4-phenylpiperidine-1-carboximidamide Chemical compound C1CN(C(=N)NCC)CCC1(C=1C=CC=CC=1)CN(C)C1=NC(N)=C(C=C(OC)C(OC)=C2)C2=N1 FHIWFUNBVHTOAO-UHFFFAOYSA-N 0.000 description 1
• JPYMPADAGRUZHK-UHFFFAOYSA-N 4-[[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]methyl]-n,4-diphenylpiperidine-1-carboxamide Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(C)CC(CC1)(C=2C=CC=CC=2)CCN1C(=O)NC1=CC=CC=C1 JPYMPADAGRUZHK-UHFFFAOYSA-N 0.000 description 1
• GWZRKLZWLCBAQZ-UHFFFAOYSA-N 4-[[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]methyl]-n,n-diethyl-4-phenylpiperidine-1-carboxamide Chemical compound C1CN(C(=O)N(CC)CC)CCC1(C=1C=CC=CC=1)CN(C)C1=NC(N)=C(C=C(OC)C(OC)=C2)C2=N1 GWZRKLZWLCBAQZ-UHFFFAOYSA-N 0.000 description 1
• UWBYYNLRIYZGDI-UHFFFAOYSA-N 4-[[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]methyl]-n-butyl-4-phenylpiperidine-1-carboxamide Chemical compound C1CN(C(=O)NCCCC)CCC1(C=1C=CC=CC=1)CN(C)C1=NC(N)=C(C=C(OC)C(OC)=C2)C2=N1 UWBYYNLRIYZGDI-UHFFFAOYSA-N 0.000 description 1
• UUDXMQSRAMXIOU-UHFFFAOYSA-N 4-[[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]methyl]-n-phenyl-4-pyridin-2-ylpiperidine-1-carboxamide Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(C)CC(CC1)(C=2N=CC=CC=2)CCN1C(=O)NC1=CC=CC=C1 UUDXMQSRAMXIOU-UHFFFAOYSA-N 0.000 description 1
• GPHIXSANDFUKOI-UHFFFAOYSA-N 4-[[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]methyl]-n-propan-2-yl-4-pyridin-2-ylpiperidine-1-carboxamide Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(C)CC1(C=2N=CC=CC=2)CCN(C(=O)NC(C)C)CC1 GPHIXSANDFUKOI-UHFFFAOYSA-N 0.000 description 1
• GZIRAQIMHQPBEB-UHFFFAOYSA-N 4-[[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]methyl]-n-propyl-4-pyridin-2-ylpiperidine-1-carboxamide Chemical compound C1CN(C(=O)NCCC)CCC1(C=1N=CC=CC=1)CN(C)C1=NC(N)=C(C=C(OC)C(OC)=C2)C2=N1 GZIRAQIMHQPBEB-UHFFFAOYSA-N 0.000 description 1
• UQBCFMNXZAPQJB-UHFFFAOYSA-N 4-[[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]methyl]-n-tert-butyl-4-phenylpiperidine-1-carboxamide Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(C)CC1(C=2C=CC=CC=2)CCN(C(=O)NC(C)(C)C)CC1 UQBCFMNXZAPQJB-UHFFFAOYSA-N 0.000 description 1
• SXIFAEWFOJETOA-UHFFFAOYSA-N 4-hydroxy-butyl Chemical group [CH2]CCCO SXIFAEWFOJETOA-UHFFFAOYSA-N 0.000 description 1
• 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
• 206010001541 Akinesia Diseases 0.000 description 1
• 206010002758 Anticipatory anxiety Diseases 0.000 description 1
• KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 1
• 239000005711 Benzoic acid Substances 0.000 description 1
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
• 206010058019 Cancer Pain Diseases 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• 239000004215 Carbon black (E152) Substances 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
• 208000001387 Causalgia Diseases 0.000 description 1
• 241000700198 Cavia Species 0.000 description 1
• 241000282693 Cercopithecidae Species 0.000 description 1
• 208000000094 Chronic Pain Diseases 0.000 description 1
• 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 description 1
• 241000938605 Crocodylia Species 0.000 description 1
• RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
• 206010012289 Dementia Diseases 0.000 description 1
• 239000004375 Dextrin Substances 0.000 description 1
• 229920001353 Dextrin Polymers 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
• 206010012735 Diarrhoea Diseases 0.000 description 1
• 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
• 208000030814 Eating disease Diseases 0.000 description 1
• LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
• 108090000790 Enzymes Proteins 0.000 description 1
• 102000004190 Enzymes Human genes 0.000 description 1
• 241000283086 Equidae Species 0.000 description 1
• 208000010228 Erectile Dysfunction Diseases 0.000 description 1
• 208000019454 Feeding and Eating disease Diseases 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• 206010057671 Female sexual dysfunction Diseases 0.000 description 1
• 108091006027 G proteins Proteins 0.000 description 1
• 102000030782 GTP binding Human genes 0.000 description 1
• 108091000058 GTP-Binding Proteins 0.000 description 1
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
• 241001272567 Hominoidea Species 0.000 description 1
• 241000282412 Homo Species 0.000 description 1
• 208000035154 Hyperesthesia Diseases 0.000 description 1
• 206010020772 Hypertension Diseases 0.000 description 1
• 206010020880 Hypertrophy Diseases 0.000 description 1
• 206010022998 Irritability Diseases 0.000 description 1
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
• 206010053236 Mixed incontinence Diseases 0.000 description 1
• 229920000881 Modified starch Polymers 0.000 description 1
• TXXHDPDFNKHHGW-CCAGOZQPSA-N Muconic acid Natural products OC(=O)\C=C/C=C\C(O)=O TXXHDPDFNKHHGW-CCAGOZQPSA-N 0.000 description 1
• 241001529936 Murinae Species 0.000 description 1
• 241000699670 Mus sp. Species 0.000 description 1
• 208000008238 Muscle Spasticity Diseases 0.000 description 1
• HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
• SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
• MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
• 206010028735 Nasal congestion Diseases 0.000 description 1
• 206010028980 Neoplasm Diseases 0.000 description 1
• 208000028389 Nerve injury Diseases 0.000 description 1
• 208000000693 Neurogenic Urinary Bladder Diseases 0.000 description 1
• 206010029279 Neurogenic bladder Diseases 0.000 description 1
• GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
• 208000001294 Nociceptive Pain Diseases 0.000 description 1
• 241000283973 Oryctolagus cuniculus Species 0.000 description 1
• 241000282579 Pan Species 0.000 description 1
• 208000018737 Parkinson disease Diseases 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• 229930182555 Penicillin Natural products 0.000 description 1
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
• 208000004983 Phantom Limb Diseases 0.000 description 1
• YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical class ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
• 229920002873 Polyethylenimine Polymers 0.000 description 1
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
• OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
• IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
• 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 description 1
• 241000283984 Rodentia Species 0.000 description 1
• 206010039897 Sedation Diseases 0.000 description 1
• PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
• UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
• 206010066218 Stress Urinary Incontinence Diseases 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
• 206010050822 Suprapubic pain Diseases 0.000 description 1
• 241000282898 Sus scrofa Species 0.000 description 1
• FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
• GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
• 208000028484 Urethral disease Diseases 0.000 description 1
• 206010065584 Urethral stenosis Diseases 0.000 description 1
• 206010047139 Vasoconstriction Diseases 0.000 description 1
• 206010052428 Wound Diseases 0.000 description 1
• 238000002441 X-ray diffraction Methods 0.000 description 1
• VDOXUIZZBLJBBA-UHFFFAOYSA-N [1-[4-[[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]methyl]-4-phenylpiperidin-1-yl]-2-methyl-1-oxopropan-2-yl] acetate Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(C)CC1(C=2C=CC=CC=2)CCN(C(=O)C(C)(C)OC(C)=O)CC1 VDOXUIZZBLJBBA-UHFFFAOYSA-N 0.000 description 1
• YVZBVPXJAWOWLK-UHFFFAOYSA-N [4-[[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]methyl]-4-(4-methoxyphenyl)piperidin-1-yl]-cyclopropylmethanone Chemical compound C1=CC(OC)=CC=C1C1(CN(C)C=2N=C3C=C(OC)C(OC)=CC3=C(N)N=2)CCN(C(=O)C2CC2)CC1 YVZBVPXJAWOWLK-UHFFFAOYSA-N 0.000 description 1
• OLPNTAPHMWBJII-UHFFFAOYSA-N [4-[[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]methyl]-4-morpholin-4-ylpiperidin-1-yl]-(furan-2-yl)methanone Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(C)CC(CC1)(N2CCOCC2)CCN1C(=O)C1=CC=CO1 OLPNTAPHMWBJII-UHFFFAOYSA-N 0.000 description 1
• OLEYAEQTUGBOSZ-UHFFFAOYSA-N [4-[[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]methyl]-4-phenylpiperidin-1-yl]-(4,5-dihydro-1h-imidazol-2-yl)methanone Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(C)CC(CC1)(C=2C=CC=CC=2)CCN1C(=O)C1=NCCN1 OLEYAEQTUGBOSZ-UHFFFAOYSA-N 0.000 description 1
• BMYMRBFZIUFQOC-UHFFFAOYSA-N [4-[[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]methyl]-4-phenylpiperidin-1-yl]-(4-methylpiperazin-1-yl)methanone Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(C)CC(CC1)(C=2C=CC=CC=2)CCN1C(=O)N1CCN(C)CC1 BMYMRBFZIUFQOC-UHFFFAOYSA-N 0.000 description 1
• OESBRFSFTMUKSQ-UHFFFAOYSA-N [4-[[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]methyl]-4-phenylpiperidin-1-yl]-(furan-2-yl)methanone Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(C)CC(CC1)(C=2C=CC=CC=2)CCN1C(=O)C1=CC=CO1 OESBRFSFTMUKSQ-UHFFFAOYSA-N 0.000 description 1
• KFLODAVHUBVKDW-UHFFFAOYSA-N [4-[[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]methyl]-4-phenylpiperidin-1-yl]-(oxan-4-yl)methanone Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(C)CC(CC1)(C=2C=CC=CC=2)CCN1C(=O)C1CCOCC1 KFLODAVHUBVKDW-UHFFFAOYSA-N 0.000 description 1
• KHNJPAKQDWWUAX-UHFFFAOYSA-N [4-[[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]methyl]-4-phenylpiperidin-1-yl]-cyclobutylmethanone Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(C)CC(CC1)(C=2C=CC=CC=2)CCN1C(=O)C1CCC1 KHNJPAKQDWWUAX-UHFFFAOYSA-N 0.000 description 1
• ICFATMOENFEDSE-UHFFFAOYSA-N [4-[[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]methyl]-4-phenylpiperidin-1-yl]-cyclopentylmethanone Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(C)CC(CC1)(C=2C=CC=CC=2)CCN1C(=O)C1CCCC1 ICFATMOENFEDSE-UHFFFAOYSA-N 0.000 description 1
• NRHHVUJONPFLOD-UHFFFAOYSA-N [4-[[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]methyl]-4-phenylpiperidin-1-yl]-morpholin-4-ylmethanone Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(C)CC(CC1)(C=2C=CC=CC=2)CCN1C(=O)N1CCOCC1 NRHHVUJONPFLOD-UHFFFAOYSA-N 0.000 description 1
• GRVTVDSSDCJVSL-UHFFFAOYSA-N [4-[[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]methyl]-4-phenylpiperidin-1-yl]-pyridin-2-ylmethanone Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(C)CC(CC1)(C=2C=CC=CC=2)CCN1C(=O)C1=CC=CC=N1 GRVTVDSSDCJVSL-UHFFFAOYSA-N 0.000 description 1
• URONBBHTOCHKLS-UHFFFAOYSA-N [4-[[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]methyl]-4-phenylpiperidin-1-yl]-pyridin-3-ylmethanone Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(C)CC(CC1)(C=2C=CC=CC=2)CCN1C(=O)C1=CC=CN=C1 URONBBHTOCHKLS-UHFFFAOYSA-N 0.000 description 1
• 230000002159 abnormal effect Effects 0.000 description 1
• 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 239000013543 active substance Substances 0.000 description 1
• 230000001154 acute effect Effects 0.000 description 1
• 125000002252 acyl group Chemical group 0.000 description 1
• 239000000853 adhesive Substances 0.000 description 1
• 230000001070 adhesive effect Effects 0.000 description 1
• 239000002671 adjuvant Substances 0.000 description 1
• 230000001800 adrenalinergic effect Effects 0.000 description 1
• 239000000670 adrenergic alpha-2 receptor antagonist Substances 0.000 description 1
• 125000003158 alcohol group Chemical group 0.000 description 1
• 229910001413 alkali metal ion Inorganic materials 0.000 description 1
• 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
• 125000005907 alkyl ester group Chemical group 0.000 description 1
• 125000005278 alkyl sulfonyloxy group Chemical group 0.000 description 1
• 125000002947 alkylene group Chemical group 0.000 description 1
• IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 description 1
• 206010053552 allodynia Diseases 0.000 description 1
• BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
• 229910052782 aluminium Inorganic materials 0.000 description 1
• WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
• 150000001409 amidines Chemical class 0.000 description 1
• 238000005576 amination reaction Methods 0.000 description 1
• 125000003277 amino group Chemical group 0.000 description 1
• 230000036592 analgesia Effects 0.000 description 1
• 229940127282 angiotensin receptor antagonist Drugs 0.000 description 1
• 238000010171 animal model Methods 0.000 description 1
• 230000008485 antagonism Effects 0.000 description 1
• 230000003070 anti-hyperalgesia Effects 0.000 description 1
• 229940005529 antipsychotics Drugs 0.000 description 1
• 239000008135 aqueous vehicle Substances 0.000 description 1
• 230000004872 arterial blood pressure Effects 0.000 description 1
• 235000021311 artificial sweeteners Nutrition 0.000 description 1
• 125000004658 aryl carbonyl amino group Chemical group 0.000 description 1
• 125000005279 aryl sulfonyloxy group Chemical group 0.000 description 1
• 239000012131 assay buffer Substances 0.000 description 1
• 239000012298 atmosphere Substances 0.000 description 1
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
• 208000027697 autoimmune lymphoproliferative syndrome due to CTLA4 haploinsuffiency Diseases 0.000 description 1
• SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
• 229940092714 benzenesulfonic acid Drugs 0.000 description 1
• 229940049706 benzodiazepine Drugs 0.000 description 1
• 125000003310 benzodiazepinyl group Chemical class N1N=C(C=CC2=C1C=CC=C2)* 0.000 description 1
• 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
• 235000010233 benzoic acid Nutrition 0.000 description 1
• RROBIDXNTUAHFW-UHFFFAOYSA-N benzotriazol-1-yloxy-tris(dimethylamino)phosphanium Chemical compound C1=CC=C2N(O[P+](N(C)C)(N(C)C)N(C)C)N=NC2=C1 RROBIDXNTUAHFW-UHFFFAOYSA-N 0.000 description 1
• 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
• 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
• SUMDYPCJJOFFON-UHFFFAOYSA-N beta-hydroxyethanesulfonic acid Natural products OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
• 239000011230 binding agent Substances 0.000 description 1
• 229920002988 biodegradable polymer Polymers 0.000 description 1
• 239000004621 biodegradable polymer Substances 0.000 description 1
• 239000013060 biological fluid Substances 0.000 description 1
• 230000033228 biological regulation Effects 0.000 description 1
• 229960000074 biopharmaceutical Drugs 0.000 description 1
• 230000015572 biosynthetic process Effects 0.000 description 1
• 239000004305 biphenyl Substances 0.000 description 1
• 235000010290 biphenyl Nutrition 0.000 description 1
• 235000019658 bitter taste Nutrition 0.000 description 1
• 239000012267 brine Substances 0.000 description 1
• 125000001246 bromo group Chemical group Br* 0.000 description 1
• KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
• MSZJEPVVQWJCIF-UHFFFAOYSA-N butylazanide Chemical compound CCCC[NH-] MSZJEPVVQWJCIF-UHFFFAOYSA-N 0.000 description 1
• AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
• 239000000920 calcium hydroxide Substances 0.000 description 1
• 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
• 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
• 235000013877 carbamide Nutrition 0.000 description 1
• 229910052799 carbon Inorganic materials 0.000 description 1
• 150000001722 carbon compounds Chemical class 0.000 description 1
• 239000001569 carbon dioxide Substances 0.000 description 1
• 229910002092 carbon dioxide Inorganic materials 0.000 description 1
• 229960004424 carbon dioxide Drugs 0.000 description 1
• 229910002091 carbon monoxide Inorganic materials 0.000 description 1
• 210000004413 cardiac myocyte Anatomy 0.000 description 1
• 235000010418 carrageenan Nutrition 0.000 description 1
• 239000000679 carrageenan Substances 0.000 description 1
• 229920001525 carrageenan Polymers 0.000 description 1
• 229940113118 carrageenan Drugs 0.000 description 1
• 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
• 150000003943 catecholamines Chemical class 0.000 description 1
• KYKAJFCTULSVSH-UHFFFAOYSA-N chloro(fluoro)methane Chemical compound F[C]Cl KYKAJFCTULSVSH-UHFFFAOYSA-N 0.000 description 1
• AOGYCOYQMAVAFD-UHFFFAOYSA-N chlorocarbonic acid Chemical class OC(Cl)=O AOGYCOYQMAVAFD-UHFFFAOYSA-N 0.000 description 1
• RCTYPNKXASFOBE-UHFFFAOYSA-M chloromercury Chemical compound [Hg]Cl RCTYPNKXASFOBE-UHFFFAOYSA-M 0.000 description 1
• 150000005753 chloropyridines Chemical class 0.000 description 1
• 238000004587 chromatography analysis Methods 0.000 description 1
• 230000001684 chronic effect Effects 0.000 description 1
• 208000022371 chronic pain syndrome Diseases 0.000 description 1
• QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 1
• 229960004170 clozapine Drugs 0.000 description 1
• 229960003920 cocaine Drugs 0.000 description 1
• 208000010877 cognitive disease Diseases 0.000 description 1
• 230000001149 cognitive effect Effects 0.000 description 1
• 208000014439 complex regional pain syndrome type 2 Diseases 0.000 description 1
• 239000000306 component Substances 0.000 description 1
• 229940125782 compound 2 Drugs 0.000 description 1
• 230000001010 compromised effect Effects 0.000 description 1
• 238000013270 controlled release Methods 0.000 description 1
• 238000007796 conventional method Methods 0.000 description 1
• 230000036461 convulsion Effects 0.000 description 1
• 238000001816 cooling Methods 0.000 description 1
• XBRXTUGRUXGBPX-DLBZAZTESA-N cyclazosin Chemical class N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N([C@@H]1CCCC[C@@H]11)CCN1C(=O)C1=CC=CO1 XBRXTUGRUXGBPX-DLBZAZTESA-N 0.000 description 1
• 125000004122 cyclic group Chemical group 0.000 description 1
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 description 1
• 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• MGNZXYYWBUKAII-UHFFFAOYSA-N cyclohexa-1,3-diene Chemical compound C1CC=CC=C1 MGNZXYYWBUKAII-UHFFFAOYSA-N 0.000 description 1
• 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
• 230000001419 dependent effect Effects 0.000 description 1
• 238000010511 deprotection reaction Methods 0.000 description 1
• 238000013461 design Methods 0.000 description 1
• 238000011161 development Methods 0.000 description 1
• 235000019425 dextrin Nutrition 0.000 description 1
• 239000008121 dextrose Substances 0.000 description 1
• 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
• 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
• 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
• 235000014113 dietary fatty acids Nutrition 0.000 description 1
• ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
• 230000003292 diminished effect Effects 0.000 description 1
• 235000014632 disordered eating Nutrition 0.000 description 1
• 238000010494 dissociation reaction Methods 0.000 description 1
• 230000005593 dissociations Effects 0.000 description 1
• 238000004821 distillation Methods 0.000 description 1
• 230000009429 distress Effects 0.000 description 1
• RUZYUOTYCVRMRZ-UHFFFAOYSA-N doxazosin Chemical compound C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 RUZYUOTYCVRMRZ-UHFFFAOYSA-N 0.000 description 1
• 229960001389 doxazosin Drugs 0.000 description 1
• 238000009510 drug design Methods 0.000 description 1
• 230000001804 emulsifying effect Effects 0.000 description 1
• 239000002702 enteric coating Substances 0.000 description 1
• 238000009505 enteric coating Methods 0.000 description 1
• 239000002532 enzyme inhibitor Substances 0.000 description 1
• 229940125532 enzyme inhibitor Drugs 0.000 description 1
• 210000002615 epidermis Anatomy 0.000 description 1
• 206010015037 epilepsy Diseases 0.000 description 1
• 229960005139 epinephrine Drugs 0.000 description 1
• CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
• 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
• ZXMOUMVMTRLYHD-UHFFFAOYSA-N ethyl 4-[[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]methyl]-4-phenylpiperidine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCC1(C=1C=CC=CC=1)CN(C)C1=NC(N)=C(C=C(OC)C(OC)=C2)C2=N1 ZXMOUMVMTRLYHD-UHFFFAOYSA-N 0.000 description 1
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
• LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
• 229940093471 ethyl oleate Drugs 0.000 description 1
• 238000000605 extraction Methods 0.000 description 1
• 210000003414 extremity Anatomy 0.000 description 1
• 239000000194 fatty acid Substances 0.000 description 1
• 229930195729 fatty acid Natural products 0.000 description 1
• 239000012091 fetal bovine serum Substances 0.000 description 1
• 238000001914 filtration Methods 0.000 description 1
• 239000006260 foam Substances 0.000 description 1
• 235000013355 food flavoring agent Nutrition 0.000 description 1
• 150000003948 formamides Chemical class 0.000 description 1
• 238000013467 fragmentation Methods 0.000 description 1
• 238000006062 fragmentation reaction Methods 0.000 description 1
• 238000004108 freeze drying Methods 0.000 description 1
• 239000001530 fumaric acid Substances 0.000 description 1
• 238000002825 functional assay Methods 0.000 description 1
• 239000007789 gas Substances 0.000 description 1
• 230000002496 gastric effect Effects 0.000 description 1
• 230000005176 gastrointestinal motility Effects 0.000 description 1
• 239000003349 gelling agent Substances 0.000 description 1
• 239000000174 gluconic acid Substances 0.000 description 1
• 235000012208 gluconic acid Nutrition 0.000 description 1
• 239000004220 glutamic acid Substances 0.000 description 1
• 235000013922 glutamic acid Nutrition 0.000 description 1
• 235000011187 glycerol Nutrition 0.000 description 1
• 230000004116 glycogenolysis Effects 0.000 description 1
• 239000008187 granular material Substances 0.000 description 1
• 239000001963 growth medium Substances 0.000 description 1
• 150000002357 guanidines Chemical class 0.000 description 1
• 125000004475 heteroaralkyl group Chemical group 0.000 description 1
• 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
• 210000000548 hind-foot Anatomy 0.000 description 1
• 239000008240 homogeneous mixture Substances 0.000 description 1
• 239000011539 homogenization buffer Substances 0.000 description 1
• 229940088597 hormone Drugs 0.000 description 1
• 239000005556 hormone Substances 0.000 description 1
• 229930195733 hydrocarbon Natural products 0.000 description 1
• 150000003840 hydrochlorides Chemical class 0.000 description 1
• 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
• 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
• 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
• 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
• 208000013403 hyperactivity Diseases 0.000 description 1
• 206010020718 hyperplasia Diseases 0.000 description 1
• 125000002883 imidazolyl group Chemical group 0.000 description 1
• 238000007654 immersion Methods 0.000 description 1
• 230000001771 impaired effect Effects 0.000 description 1
• 239000007943 implant Substances 0.000 description 1
• 201000001881 impotence Diseases 0.000 description 1
• 238000000338 in vitro Methods 0.000 description 1
• 239000005414 inactive ingredient Substances 0.000 description 1
• 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
• 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
• 125000001041 indolyl group Chemical group 0.000 description 1
• 238000002329 infrared spectrum Methods 0.000 description 1
• 230000002401 inhibitory effect Effects 0.000 description 1
• 230000005764 inhibitory process Effects 0.000 description 1
• 230000000977 initiatory effect Effects 0.000 description 1
• 230000003993 interaction Effects 0.000 description 1
• 239000000543 intermediate Substances 0.000 description 1
• 238000001361 intraarterial administration Methods 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000007913 intrathecal administration Methods 0.000 description 1
• 238000007915 intraurethral administration Methods 0.000 description 1
• 125000002346 iodo group Chemical group I* 0.000 description 1
• 150000002500 ions Chemical class 0.000 description 1
• 230000000622 irritating effect Effects 0.000 description 1
• 239000012948 isocyanate Substances 0.000 description 1
• 150000002513 isocyanates Chemical class 0.000 description 1
• 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
• 238000002955 isolation Methods 0.000 description 1
• 125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 1
• 239000004310 lactic acid Substances 0.000 description 1
• 235000014655 lactic acid Nutrition 0.000 description 1
• 229960000448 lactic acid Drugs 0.000 description 1
• 239000003446 ligand Substances 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 150000002632 lipids Chemical class 0.000 description 1
• 230000004807 localization Effects 0.000 description 1
• 210000003141 lower extremity Anatomy 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 210000004072 lung Anatomy 0.000 description 1
• ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
• 239000001095 magnesium carbonate Substances 0.000 description 1
• 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
• 235000019341 magnesium sulphate Nutrition 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
• 239000011976 maleic acid Substances 0.000 description 1
• 229940098895 maleic acid Drugs 0.000 description 1
• 239000001630 malic acid Substances 0.000 description 1
• 235000011090 malic acid Nutrition 0.000 description 1
• 229940099690 malic acid Drugs 0.000 description 1
• 229960002510 mandelic acid Drugs 0.000 description 1
• 238000005259 measurement Methods 0.000 description 1
• 230000001404 mediated effect Effects 0.000 description 1
• 108020004999 messenger RNA Proteins 0.000 description 1
• 229910021645 metal ion Inorganic materials 0.000 description 1
• 229940098779 methanesulfonic acid Drugs 0.000 description 1
• 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
• RFKMCNOHBTXSMU-UHFFFAOYSA-N methoxyflurane Chemical compound COC(F)(F)C(Cl)Cl RFKMCNOHBTXSMU-UHFFFAOYSA-N 0.000 description 1
• 229960002455 methoxyflurane Drugs 0.000 description 1
• 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
• 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
• 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
• 125000004458 methylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])[H] 0.000 description 1
• 229960002216 methylparaben Drugs 0.000 description 1
• 239000008108 microcrystalline cellulose Substances 0.000 description 1
• 229940016286 microcrystalline cellulose Drugs 0.000 description 1
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
• 150000007522 mineralic acids Chemical class 0.000 description 1
• 235000019426 modified starch Nutrition 0.000 description 1
• 238000012544 monitoring process Methods 0.000 description 1
• 125000002757 morpholinyl group Chemical group 0.000 description 1
• 239000002324 mouth wash Substances 0.000 description 1
• 210000002464 muscle smooth vascular Anatomy 0.000 description 1
• VOVZXURTCKPRDQ-CQSZACIVSA-N n-[4-[chloro(difluoro)methoxy]phenyl]-6-[(3r)-3-hydroxypyrrolidin-1-yl]-5-(1h-pyrazol-5-yl)pyridine-3-carboxamide Chemical compound C1[C@H](O)CCN1C1=NC=C(C(=O)NC=2C=CC(OC(F)(F)Cl)=CC=2)C=C1C1=CC=NN1 VOVZXURTCKPRDQ-CQSZACIVSA-N 0.000 description 1
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
• BSOVIALCHYCZQT-UHFFFAOYSA-N n-methylpiperidine-1-carboxamide Chemical compound CNC(=O)N1CCCCC1 BSOVIALCHYCZQT-UHFFFAOYSA-N 0.000 description 1
• 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• DHOSAMAUFVBGFE-UHFFFAOYSA-N n-pyridin-2-ylpiperidine-1-carboxamide Chemical compound C1CCCCN1C(=O)NC1=CC=CC=N1 DHOSAMAUFVBGFE-UHFFFAOYSA-N 0.000 description 1
• KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
• 125000001624 naphthyl group Chemical group 0.000 description 1
• 235000021096 natural sweeteners Nutrition 0.000 description 1
• 230000008764 nerve damage Effects 0.000 description 1
• 210000001640 nerve ending Anatomy 0.000 description 1
• 230000000955 neuroendocrine Effects 0.000 description 1
• 230000000926 neurological effect Effects 0.000 description 1
• 230000002981 neuropathic effect Effects 0.000 description 1
• 201000001119 neuropathy Diseases 0.000 description 1
• 230000007823 neuropathy Effects 0.000 description 1
• 229960002715 nicotine Drugs 0.000 description 1
• SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
• 229910017604 nitric acid Inorganic materials 0.000 description 1
• 150000002825 nitriles Chemical class 0.000 description 1
• 125000004433 nitrogen atom Chemical group N* 0.000 description 1
• 230000003040 nociceptive effect Effects 0.000 description 1
• 230000009871 nonspecific binding Effects 0.000 description 1
• 229960002748 norepinephrine Drugs 0.000 description 1
• SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
• 239000012038 nucleophile Substances 0.000 description 1
• 230000000414 obstructive effect Effects 0.000 description 1
• 239000003921 oil Substances 0.000 description 1
• 235000019198 oils Nutrition 0.000 description 1
• 235000008390 olive oil Nutrition 0.000 description 1
• 239000004006 olive oil Substances 0.000 description 1
• 229940127240 opiate Drugs 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 235000005985 organic acids Nutrition 0.000 description 1
• 150000002895 organic esters Chemical class 0.000 description 1
• 238000006053 organic reaction Methods 0.000 description 1
• 239000003960 organic solvent Substances 0.000 description 1
• 125000002971 oxazolyl group Chemical group 0.000 description 1
• 125000004043 oxo group Chemical group O=* 0.000 description 1
• 239000001301 oxygen Substances 0.000 description 1
• 238000012856 packing Methods 0.000 description 1
• 230000008533 pain sensitivity Effects 0.000 description 1
• NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 1
• YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
• 208000019906 panic disease Diseases 0.000 description 1
• FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 239000006072 paste Substances 0.000 description 1
• 235000010603 pastilles Nutrition 0.000 description 1
• 230000036285 pathological change Effects 0.000 description 1
• 239000001814 pectin Substances 0.000 description 1
• 235000010987 pectin Nutrition 0.000 description 1
• 229920001277 pectin Polymers 0.000 description 1
• 239000008188 pellet Substances 0.000 description 1
• 239000003961 penetration enhancing agent Substances 0.000 description 1
• 229940049954 penicillin Drugs 0.000 description 1
• 208000033808 peripheral neuropathy Diseases 0.000 description 1
• 239000000825 pharmaceutical preparation Substances 0.000 description 1
• MRBDMNSDAVCSSF-UHFFFAOYSA-N phentolamine Chemical compound C1=CC(C)=CC=C1N(C=1C=C(O)C=CC=1)CC1=NCCN1 MRBDMNSDAVCSSF-UHFFFAOYSA-N 0.000 description 1
• 229960001999 phentolamine Drugs 0.000 description 1
• 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000004193 piperazinyl group Chemical group 0.000 description 1
• 125000003386 piperidinyl group Chemical group 0.000 description 1
• IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
• 229920003023 plastic Polymers 0.000 description 1
• 239000004033 plastic Substances 0.000 description 1
• 229920000747 poly(lactic acid) Polymers 0.000 description 1
• 229940113116 polyethylene glycol 1000 Drugs 0.000 description 1
• 229940057838 polyethylene glycol 4000 Drugs 0.000 description 1
• 239000004626 polylactic acid Substances 0.000 description 1
• 229920001184 polypeptide Polymers 0.000 description 1
• 230000001144 postural effect Effects 0.000 description 1
• 229910052700 potassium Inorganic materials 0.000 description 1
• 239000011591 potassium Substances 0.000 description 1
• WSHYKIAQCMIPTB-UHFFFAOYSA-M potassium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [K+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 WSHYKIAQCMIPTB-UHFFFAOYSA-M 0.000 description 1
• 238000002953 preparative HPLC Methods 0.000 description 1
• 230000002335 preservative effect Effects 0.000 description 1
• 108090000765 processed proteins & peptides Proteins 0.000 description 1
• 102000004196 processed proteins & peptides Human genes 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
• 239000003380 propellant Substances 0.000 description 1
• 230000000069 prophylactic effect Effects 0.000 description 1
• 235000019260 propionic acid Nutrition 0.000 description 1
• 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 230000002685 pulmonary effect Effects 0.000 description 1
• 125000003373 pyrazinyl group Chemical group 0.000 description 1
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
• 125000004076 pyridyl group Chemical group 0.000 description 1
• 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
• 125000000168 pyrrolyl group Chemical group 0.000 description 1
• IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
• 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
• 238000003653 radioligand binding assay Methods 0.000 description 1
• 229940044551 receptor antagonist Drugs 0.000 description 1
• 239000002464 receptor antagonist Substances 0.000 description 1
• 238000011084 recovery Methods 0.000 description 1
• 238000001953 recrystallisation Methods 0.000 description 1
• 239000011347 resin Substances 0.000 description 1
• 229920005989 resin Polymers 0.000 description 1
• 210000002345 respiratory system Anatomy 0.000 description 1
• 239000000837 restrainer Substances 0.000 description 1
• 238000012552 review Methods 0.000 description 1
• 229960004889 salicylic acid Drugs 0.000 description 1
• 229920006395 saturated elastomer Polymers 0.000 description 1
• 229930195734 saturated hydrocarbon Natural products 0.000 description 1
• 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 125000005930 sec-butyloxycarbonyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 1
• 230000036280 sedation Effects 0.000 description 1
• 230000035807 sensation Effects 0.000 description 1
• 235000019615 sensations Nutrition 0.000 description 1
• 230000001953 sensory effect Effects 0.000 description 1
• 229920002379 silicone rubber Polymers 0.000 description 1
• 239000004945 silicone rubber Substances 0.000 description 1
• 210000003491 skin Anatomy 0.000 description 1
• 208000020685 sleep-wake disease Diseases 0.000 description 1
• 235000017557 sodium bicarbonate Nutrition 0.000 description 1
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
• 239000011780 sodium chloride Substances 0.000 description 1
• 229910052938 sodium sulfate Inorganic materials 0.000 description 1
• 235000011152 sodium sulphate Nutrition 0.000 description 1
• 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
• 239000001593 sorbitan monooleate Substances 0.000 description 1
• 235000011069 sorbitan monooleate Nutrition 0.000 description 1
• 229940035049 sorbitan monooleate Drugs 0.000 description 1
• 208000018198 spasticity Diseases 0.000 description 1
• 230000003595 spectral effect Effects 0.000 description 1
• 238000002798 spectrophotometry method Methods 0.000 description 1
• 210000001032 spinal nerve Anatomy 0.000 description 1
• 238000013222 sprague-dawley male rat Methods 0.000 description 1
• 229960005322 streptomycin Drugs 0.000 description 1
• 230000035882 stress Effects 0.000 description 1
• 208000022170 stress incontinence Diseases 0.000 description 1
• 238000006467 substitution reaction Methods 0.000 description 1
• NVBFHJWHLNUMCV-UHFFFAOYSA-N sulfamide Chemical class NS(N)(=O)=O NVBFHJWHLNUMCV-UHFFFAOYSA-N 0.000 description 1
• QAHVHSLSRLSVGS-UHFFFAOYSA-N sulfamoyl chloride Chemical class NS(Cl)(=O)=O QAHVHSLSRLSVGS-UHFFFAOYSA-N 0.000 description 1
• 229940124530 sulfonamide Drugs 0.000 description 1
• 150000003456 sulfonamides Chemical class 0.000 description 1
• 239000011593 sulfur Substances 0.000 description 1
• YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical class ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
• 230000000153 supplemental effect Effects 0.000 description 1
• 239000004094 surface-active agent Substances 0.000 description 1
• 210000002820 sympathetic nervous system Anatomy 0.000 description 1
• 238000002636 symptomatic treatment Methods 0.000 description 1
• 239000006188 syrup Substances 0.000 description 1
• 235000020357 syrup Nutrition 0.000 description 1
• 230000009897 systematic effect Effects 0.000 description 1
• 239000000454 talc Substances 0.000 description 1
• 229910052623 talc Inorganic materials 0.000 description 1
• 235000002906 tartaric acid Nutrition 0.000 description 1
• 239000011975 tartaric acid Substances 0.000 description 1
• 230000028016 temperature homeostasis Effects 0.000 description 1
• VCKUSRYTPJJLNI-UHFFFAOYSA-N terazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1CCCO1 VCKUSRYTPJJLNI-UHFFFAOYSA-N 0.000 description 1
• 229960001693 terazosin Drugs 0.000 description 1
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• DXUIHSPYYZEIGS-UHFFFAOYSA-N tert-butyl n-[4-[4-[[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]methyl]-4-phenylpiperidin-1-yl]-2-methyl-4-oxobutan-2-yl]carbamate Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(C)CC1(C=2C=CC=CC=2)CCN(C(=O)CC(C)(C)NC(=O)OC(C)(C)C)CC1 DXUIHSPYYZEIGS-UHFFFAOYSA-N 0.000 description 1
• UJJLJRQIPMGXEZ-UHFFFAOYSA-N tetrahydro-2-furoic acid Chemical compound OC(=O)C1CCCO1 UJJLJRQIPMGXEZ-UHFFFAOYSA-N 0.000 description 1
• 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
• RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 1
• 125000000335 thiazolyl group Chemical group 0.000 description 1
• 230000008719 thickening Effects 0.000 description 1
• 125000001544 thienyl group Chemical group 0.000 description 1
• 125000005297 thienyloxy group Chemical group S1C(=CC=C1)O* 0.000 description 1
• 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 239000012049 topical pharmaceutical composition Substances 0.000 description 1
• 230000037317 transdermal delivery Effects 0.000 description 1
• 102000027257 transmembrane receptors Human genes 0.000 description 1
• 108091008578 transmembrane receptors Proteins 0.000 description 1
• 238000011269 treatment regimen Methods 0.000 description 1
• IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 1
• CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
• 229940029284 trichlorofluoromethane Drugs 0.000 description 1
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
• 229960000281 trometamol Drugs 0.000 description 1
• 150000003672 ureas Chemical class 0.000 description 1
• 201000001988 urethral stricture Diseases 0.000 description 1
• 230000002792 vascular Effects 0.000 description 1
• 230000025033 vasoconstriction Effects 0.000 description 1
• 235000015112 vegetable and seed oil Nutrition 0.000 description 1
• 239000008158 vegetable oil Substances 0.000 description 1
• 239000011345 viscous material Substances 0.000 description 1
• 238000009736 wetting Methods 0.000 description 1
• UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1